Answers are grounded in this paper and cite their sources.
Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy.
No takes yet. Share an insight, caveat, or question.
Mak et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: